The FDA approval is a major value inflection point for Arvinas, likely driving a significant positive stock reaction. Monitor for the selection of a third-party commercialization partner and initial launch metrics. The $50M milestone provides near-term cash, but long-term value depends on commercial uptake and label expansion.
Price Chart
Executive Summary
Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced breast cancer, the first-ever approved PROTAC therapy. The approval came ahead of the June 5 PDUFA date, and Arvinas will receive a $50M milestone payment from partner Pfizer. This transformative milestone validates the PROTAC platform and provides a new treatment option in a high-need setting.
Key Facts
- FDA approved VEPPANU (vepdegestrant) for ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after prior endocrine therapy.
- First-and-only FDA-approved PROTAC (protein degrader) therapy.
- Approval received ahead of the June 5, 2026 PDUFA date.
- In the Phase 3 VERITAC-2 trial, VEPPANU reduced risk of disease progression or death by 43% vs fulvestrant (HR 0.57, p=0.0001) in ESR1-mutated patients.
- Arvinas will receive a $50M development milestone payment from Pfizer, offset by amounts owed to Yale University.
- Arvinas and Pfizer remain on track to select a third-party commercial partner.
Financial Impact
$50 million milestone payment from Pfizer (net of Yale obligations); future commercial revenue potential for a first-in-class drug
Risk Factors
- Commercial execution risk given Arvinas and Pfizer are outsourcing commercialization
- Potential safety concerns (QT prolongation, liver enzyme elevations) may limit use
- Competition from other CDK4/6 inhibitor combinations and emerging therapies
- ESR1-mutant patient population limits addressable market (~40-50% of ER+ patients)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001628280-26-029210 |
| Document: fdaapprovalpressrelease_.htm | 0001628280-26-029210 |
| Document: 0001628280-26-029210-index-headers.html | 0001628280-26-029210 |
| Document: 0001628280-26-029210-index.html | 0001628280-26-029210 |
| Document: 0001628280-26-029210.txt | 0001628280-26-029210 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 4, 2026 28d ago | 144 | $9.08 $8.26 | ▼ −9.03% | ▼ −7.91% | $7.41 (−18.39%) |
Jun 22, 2026 14w ago | 8-K | $8.14 $8.29 | ▲ +1.84% | ▲ +0.83% | $7.41 (−8.97%) |
Jun 2, 2026 17w ago | 8-K | $7.70 $6.98 | ▲ +9.35% | ▲ +5.53% | $7.41 (+3.77%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | 8-K | $9.57 $8.78 | ▼ −8.26% | ▼ −8.33% | $7.41 (−22.57%) |
May 12, 2026 20w ago | Press Release | $9.57 $8.78 | ▲ +8.26% | ▲ +8.33% | $7.41 (+22.57%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 8, 2026 20w ago | 144 | $9.66 $8.78 | ▼ −9.11% | ▼ −9.02% | $7.41 (−23.29%) |
May 5, 2026 21w ago | Press Release | $10.61 $9.57 | ▲ +9.80% | ▲ +11.79% | $7.41 (+30.16%) |
May 1, 2026 22w ago | 8-K | $10.51 $10.19 | ▼ −3.04% | ▼ −5.39% | $7.41 (−29.50%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access